14 days of Premium, free.
Every scanner with live hit rates + the Market Pulse risk flag that tells you when to get defensive. No card required.
Start trial →
Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026
CONX vs ABVC: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
As of Nov 16, 2026, ABVC BioPharma, Inc. (ABVC) is the stronger overall head-to-head candidate over CONX (CONX) in the Tradestie Institutional Equity Comparison Engine, winning 7–1 core matrix metrics and 3–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). CONX carries a Unified Composite Score of 42.0/100 (HOLD) at $2.66 (N/M Forward P/E, N/A operating margin), whereas ABVC carries 39.0/100 (SELL) at $0.94 (N/M Forward P/E, 0.0% operating margin).
Composite vs. Pillar Nuance: While CONX currently prints a higher short-term Unified Composite Score (42.0/100 HOLD vs. ABVC 39.0/100 SELL), ABVC captures the overall institutional head-to-head verdict (7–1 matrix metrics and 3–1 across the 6 pillars) due to superior fundamental profitability (0.0% vs. N/A operating margin) and revenue trajectory (+104.5% vs. N/A YoY).
Technical & Structure Timing Caution: CONX is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 29.8); meanwhile ABVC trades in a Neutral technical trend (UNCLASSIFIED options phase, RSI 43.7). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on CONX vs ABVC. Trailing 12-month operating profitability (CONX N/A vs ABVC 0.0%) and valuation multiples (CONX N/M vs ABVC N/M Forward P/E) are benchmarked directly in Pillar 4 below.
Competes within the Biotechnology value chain with $24.5M market capitalization and 0.0% operating margin.
OpEx & R&D ReinvestmentN/A
90D Engineering Disclosures0 Published
Investor FAQ CONX vs ABVC Key Questions & Quantitative Answers
As of Nov 16, 2026, ABVC BioPharma, Inc. (ABVC) is the stronger overall head-to-head candidate over CONX (CONX) in the Tradestie Institutional Equity Comparison Engine, winning 7–1 core matrix metrics and 3–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). CONX carries a Unified Composite Score of 42.0/100 (HOLD) at $2.66 (N/M Forward P/E, N/A operating margin), whereas ABVC carries 39.0/100 (SELL) at $0.94 (N/M Forward P/E, 0.0% operating margin). Composite vs. Pillar Nuance: While CONX currently prints a higher short-term Unified Composite Score (42.0/100 HOLD vs. ABVC 39.0/100 SELL), ABVC captures the overall institutional head-to-head verdict (7–1 matrix metrics and 3–1 across the 6 pillars) due to superior fundamental profitability (0.0% vs. N/A operating margin) and revenue trajectory (+104.5% vs. N/A YoY). Technical & Structure Timing Caution: CONX is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 29.8); meanwhile ABVC trades in a Neutral technical trend (UNCLASSIFIED options phase, RSI 43.7). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
ABVC leads the Growth & Scale pillar: CONX posts N/A YoY revenue growth and N/A YoY earnings growth on N/A TTM revenue (N/A gross margin, N/A operating margin), compared with ABVC at +104.5% YoY revenue growth and +0.0% YoY earnings growth on $797,916 TTM revenue (100.0% gross margin, 0.0% operating margin). On trailing 12-month operating scale, CONX generates N/A in USD-normalized revenue versus $797,916 for ABVC. In operating R&D and SG&A reinvestment, CONX deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for ABVC.
ABVC screens cheaper on headline valuation multiples. CONX trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported cash flow margin), whereas ABVC trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 30.8x EV/Revenue (unreported EBITDA margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against CONX (N/A ROE) versus ABVC (-52.7% ROE) capital efficiency.
In options market volatility and institutional positioning, CONX carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (4.88β · 135% Vol realized risk). By comparison, ABVC carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (1.34β · 56% Vol realized risk).
Cross-Compare 1-Click Peer Rivalries & Single-Stock Research
Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.